Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies

L. S. Massad, E. Wagley, L. Winkelman, S. Lincoln, E. L. Yordan, Koenraad De Geest, G. D. Wilbanks

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: to determine response rates, survival, and toxicity of a regimen of mitomycin-C and 5-fluorouracil in patients previously treated with platinum-based combinations for ovarian cancer and related gynecologic malignancies. Patients and methods: retrospective chart review of all cases of persistent or recurrent ovarian, fallopian tube, and peritoneal carcinoma treated with mitomycin-C 7 mg/m2 followed by continuous infusion of 5-fluorouracil 600 mg/m2/day over 4 days. Results: 26 patients were treated after a median of 2 prior platinum-based regimens, 22 with ovarian cancer, 3 with peritoneal cancer, and one with fallopian tube cancer. Only 2 patients completed 6 or more cycles. 2 patients had partial responses (8%); no complete responses were seen. 24 patients died a median of 3 months after the initiation of therapy, while 2 patients were alive 4 and 8 months after beginning therapy. All deaths were attributable to disease, not complications of treatment. 8 patients required dose modification or treatment delay for toxicity. Nine patients required a total of 11 unscheduled admissions. Conclusions: toxicity attributable to mitomycin-C/5-fluorouracil therapy of ovarian cancer is acceptable, but responses are few. More effective alternative should be sought.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalEuropean Journal of Gynaecological Oncology
Volume15
Issue number5
StatePublished - 1994
Externally publishedYes

Fingerprint

Mitomycin
Platinum
Fluorouracil
Ovarian Neoplasms
Neoplasms
Therapeutics
Fallopian Tube Neoplasms
Fallopian Tubes
Survival Rate
Carcinoma

Keywords

  • 5-fluorouracil
  • mitomycin-C
  • ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies. / Massad, L. S.; Wagley, E.; Winkelman, L.; Lincoln, S.; Yordan, E. L.; De Geest, Koenraad; Wilbanks, G. D.

In: European Journal of Gynaecological Oncology, Vol. 15, No. 5, 1994, p. 337-342.

Research output: Contribution to journalArticle

Massad, L. S. ; Wagley, E. ; Winkelman, L. ; Lincoln, S. ; Yordan, E. L. ; De Geest, Koenraad ; Wilbanks, G. D. / Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies. In: European Journal of Gynaecological Oncology. 1994 ; Vol. 15, No. 5. pp. 337-342.
@article{27f4a8ebbe424f3bbd01c89b390a9320,
title = "Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies",
abstract = "Purpose: to determine response rates, survival, and toxicity of a regimen of mitomycin-C and 5-fluorouracil in patients previously treated with platinum-based combinations for ovarian cancer and related gynecologic malignancies. Patients and methods: retrospective chart review of all cases of persistent or recurrent ovarian, fallopian tube, and peritoneal carcinoma treated with mitomycin-C 7 mg/m2 followed by continuous infusion of 5-fluorouracil 600 mg/m2/day over 4 days. Results: 26 patients were treated after a median of 2 prior platinum-based regimens, 22 with ovarian cancer, 3 with peritoneal cancer, and one with fallopian tube cancer. Only 2 patients completed 6 or more cycles. 2 patients had partial responses (8{\%}); no complete responses were seen. 24 patients died a median of 3 months after the initiation of therapy, while 2 patients were alive 4 and 8 months after beginning therapy. All deaths were attributable to disease, not complications of treatment. 8 patients required dose modification or treatment delay for toxicity. Nine patients required a total of 11 unscheduled admissions. Conclusions: toxicity attributable to mitomycin-C/5-fluorouracil therapy of ovarian cancer is acceptable, but responses are few. More effective alternative should be sought.",
keywords = "5-fluorouracil, mitomycin-C, ovarian cancer",
author = "Massad, {L. S.} and E. Wagley and L. Winkelman and S. Lincoln and Yordan, {E. L.} and {De Geest}, Koenraad and Wilbanks, {G. D.}",
year = "1994",
language = "English (US)",
volume = "15",
pages = "337--342",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "5",

}

TY - JOUR

T1 - Salvage mitomycin/5-fluorouracil after platinum-based therapy for women with advanced ovarian cancer and related gynecologic malignancies

AU - Massad, L. S.

AU - Wagley, E.

AU - Winkelman, L.

AU - Lincoln, S.

AU - Yordan, E. L.

AU - De Geest, Koenraad

AU - Wilbanks, G. D.

PY - 1994

Y1 - 1994

N2 - Purpose: to determine response rates, survival, and toxicity of a regimen of mitomycin-C and 5-fluorouracil in patients previously treated with platinum-based combinations for ovarian cancer and related gynecologic malignancies. Patients and methods: retrospective chart review of all cases of persistent or recurrent ovarian, fallopian tube, and peritoneal carcinoma treated with mitomycin-C 7 mg/m2 followed by continuous infusion of 5-fluorouracil 600 mg/m2/day over 4 days. Results: 26 patients were treated after a median of 2 prior platinum-based regimens, 22 with ovarian cancer, 3 with peritoneal cancer, and one with fallopian tube cancer. Only 2 patients completed 6 or more cycles. 2 patients had partial responses (8%); no complete responses were seen. 24 patients died a median of 3 months after the initiation of therapy, while 2 patients were alive 4 and 8 months after beginning therapy. All deaths were attributable to disease, not complications of treatment. 8 patients required dose modification or treatment delay for toxicity. Nine patients required a total of 11 unscheduled admissions. Conclusions: toxicity attributable to mitomycin-C/5-fluorouracil therapy of ovarian cancer is acceptable, but responses are few. More effective alternative should be sought.

AB - Purpose: to determine response rates, survival, and toxicity of a regimen of mitomycin-C and 5-fluorouracil in patients previously treated with platinum-based combinations for ovarian cancer and related gynecologic malignancies. Patients and methods: retrospective chart review of all cases of persistent or recurrent ovarian, fallopian tube, and peritoneal carcinoma treated with mitomycin-C 7 mg/m2 followed by continuous infusion of 5-fluorouracil 600 mg/m2/day over 4 days. Results: 26 patients were treated after a median of 2 prior platinum-based regimens, 22 with ovarian cancer, 3 with peritoneal cancer, and one with fallopian tube cancer. Only 2 patients completed 6 or more cycles. 2 patients had partial responses (8%); no complete responses were seen. 24 patients died a median of 3 months after the initiation of therapy, while 2 patients were alive 4 and 8 months after beginning therapy. All deaths were attributable to disease, not complications of treatment. 8 patients required dose modification or treatment delay for toxicity. Nine patients required a total of 11 unscheduled admissions. Conclusions: toxicity attributable to mitomycin-C/5-fluorouracil therapy of ovarian cancer is acceptable, but responses are few. More effective alternative should be sought.

KW - 5-fluorouracil

KW - mitomycin-C

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028022790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028022790&partnerID=8YFLogxK

M3 - Article

C2 - 7828601

AN - SCOPUS:0028022790

VL - 15

SP - 337

EP - 342

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 5

ER -